Immunis Secures $25 Million in Series A-1 Funding to Advance Clinical Trials

Immunis, Inc., a clinical-stage biotechnology company focusing on developing multi-active biologics to address immune dysregulation associated with aging and diseases, has successfully raised $25 million in its Series A-1 financing round. The funding will support two Phase 2 clinical trials aimed at addressing critical unmet medical needs.

Immunis Secures $25 Million in Series A-1 Funding to Advance Clinical Trials
Immunis Secures $25 Million in Series A-1 Funding to Advance Clinical Trials

The investment round saw continued backing from major existing investors, including Remiges Ventures, Continuum Health Ventures, and BOLD Capital Partners, alongside new contributions from LifeSpan Vision Ventures, JLS Fund, and a leading global insurance company.

The biotech company has gained momentum after its Phase 1/2a clinical trial, which demonstrated the safety and tolerability of its investigational therapy, IMM01-STEM, in elderly patients with age-related muscle loss. The trial highlighted the absence of serious adverse events and revealed notable improvements in patients’ quality of life. Following these promising results, the U.S. Food and Drug Administration (FDA) granted clearance for a Phase 2 trial to explore the therapy’s efficacy in addressing muscle atrophy and metabolic dysfunction among sarcopenic, overweight, and obese elderly individuals.

Speaking about the significance of this milestone, Mark Cabato, Chief Business Officer of Immunis, stated, “Our Phase 1/2a data in nine elderly patients showed our therapy to be safe with no serious adverse events. Additionally, patients experienced striking improvements in quality-of-life measures related to physical function and pain as well as a clinically relevant increase in gait speed.” He added that the upcoming randomized and controlled studies aim to demonstrate the broader applicability of IMM01-STEM across various medical conditions.

Preclinical research has further supported the potential of this innovative therapy. Studies published in respected journals such as GeroScience and Aging Cell demonstrated the treatment’s ability to reverse muscle atrophy, improve muscle functionality, enhance metabolism, and reduce body and liver fat in aged mouse models. These findings reinforce the scientific foundation of Immunis’ multi-active biologics, positioning the company as a leader in stem cell-derived therapies currently in clinical trials.

Discussing the company’s broader mission, Cabato expressed gratitude for the support received from their board and investors. “We are grateful for the support of our Board and investors for our mission to maximize health and minimize disease through the development of novel, stem cell-derived therapies,” he noted.